Evidence map›Paper›PMID 34588847›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2021

Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis.

Mountasser Al-Mouqdad, Khalid Eljaaly, Ayman Abdalgader, Maha Al-Anazi, Muhammed Taha, Arwa Alshaibani, Raneem Asfour, Thanaa Khalil, Suzan Asfour

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Mountasser Al-MouqdadNeonatal Intensive Care Unit, Hospital of Paediatrics, King Saud Medical City, Riyadh, Saudi Arabia.
Khalid EljaalyFaculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Ayman AbdalgaderNeonatal Intensive Care Unit, Hospital of Paediatrics, King Saud Medical City, Riyadh, Saudi Arabia.
Maha Al-AnaziPharmacy Department, Pharmaceutical Care Services, King Saud Medical City, Riyadh, Saudi Arabia.
Muhammed TahaPharmacy Department, Pharmaceutical Care Services, King Saud Medical City, Riyadh, Saudi Arabia.
Arwa AlshaibaniGeneral Paediatrics Department, Hospital of Paediatrics, King Saud Medical City, Riyadh, Saudi Arabia.
Raneem AsfourPharmacy College, Jordan University of Science and Technology, Irbid, Jordan.
Thanaa KhalilObstetrics and Gynecology Department, Maternity Hospital, King Saud Medical City, Riyadh, Saudi Arabia.
Suzan AsfourClinical Pharmacy Department, Pharmaceutical Care Services, King Saud Medical City, Riyadh, Saudi Arabia.
King Saud Medical City · SAJordan University of Science and Technology · JOKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing resistance of microorganisms to antibiotics for the treatment of late-onset sepsis (LOS) in premature infants has led physicians to use antibiotics that are not well studied in neonatal populations. We aimed to determine the efficacy and safety of colistin and fluoroquinolone for the treatment of persistent LOS. We retrospectively reviewed infants with gram-negative LOS, who received either colistin or fluoroquinolone therapy, to determine if there was a significant difference in kidney and liver function tests and electrolyte levels before, during, and at the end of the treatment. Infants who received colistin and fluoroquinolone had 17 and 34 positive cultures with gram-negative organisms, respectively. Multi-drug resistant organisms were more common in infants who received colistin than in those who received fluoroquinolone. Microbiological clearance was found to be higher in infants treated with fluoroquinolone than in those treated with colistin. In both the groups, the median levels of kidney and liver function tests and electrolytes showed a significant increase during the treatment. The prescription of colistin and fluoroquinolones should be reserved for cases with no other safe and effective alternatives.

Indexed as

AntibioticsColistinFluoroquinoloneLate-onset sepsisMulti-drug resistant organismsPremature infants

Identifiers

PMID34588847
PMCPMC8463448
OpenAlexW3191076042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.